Neradil Jakub, Kyr Michal, Polaskova Kristyna, Kren Leos, Macigova Petra, Skoda Jan, Sterba Jaroslav, Veselska Renata
Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czechia.
Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno, Masaryk University, Brno, Czechia.
Front Oncol. 2019 Sep 20;9:930. doi: 10.3389/fonc.2019.00930. eCollection 2019.
The specific targeting of signal transduction by low-molecular-weight inhibitors or monoclonal antibodies represents a very promising personalized treatment strategy in pediatric oncology. In this study, we present the successful and clinically relevant use of commercially available phospho-protein arrays for analyses of the phosphorylation profiles of a broad spectrum of receptor tyrosine kinases and their downstream signaling proteins in tumor tissue samples. Although these arrays were made for research purposes on human biological samples, they have already been used by several authors to profile various tumor types. Our study performed a systematic analysis of the advantages and pitfalls of the use of this method for personalized clinical medicine. In certain clinical cases and their series, we demonstrated the important aspects of data processing and evaluation, the use of phospho-protein arrays for single sample and serial sample analyses, and the validation of obtained results by immunohistochemistry, as well as the possibilities of this method for the hierarchical clustering of pediatric solid tumors. Our results clearly show that phospho-protein arrays are apparently useful for the clinical consideration of druggable molecular targets within a specific tumor. Thus, their potential validation for diagnostic purposes may substantially improve the personalized approach in the treatment of relapsed or refractory solid tumors.
低分子量抑制剂或单克隆抗体对信号转导的特异性靶向代表了儿科肿瘤学中一种非常有前景的个性化治疗策略。在本研究中,我们展示了商业可用的磷酸化蛋白阵列在肿瘤组织样本中分析多种受体酪氨酸激酶及其下游信号蛋白磷酸化谱方面的成功应用及临床相关性。尽管这些阵列是用于对人类生物样本的研究目的,但已有多位作者将其用于分析各种肿瘤类型。我们的研究对该方法在个性化临床医学中的应用优势和缺陷进行了系统分析。在某些临床病例及其系列研究中,我们展示了数据处理与评估的重要方面、磷酸化蛋白阵列在单样本和系列样本分析中的应用、通过免疫组织化学对所得结果的验证,以及该方法用于儿科实体瘤分层聚类的可能性。我们的结果清楚地表明,磷酸化蛋白阵列显然有助于在特定肿瘤内对可成药分子靶点进行临床考量。因此,其用于诊断目的的潜在验证可能会显著改善复发性或难治性实体瘤治疗中的个性化方法。